Ramaswamy - Axovant trade explained?

I came across an interesting WSJ article on Vivek Ramaswamy (https://www.nytimes.com/2023/06/27/us/politics/vivek-ramaswamy-wealth.h…). 

I was wondering if anyone could help explain how it was possible for Axovant to buy a drug for $5 million and take it public 6 months later for $3 billion? Does this sort of opportunity still exist in the biotech world?

14 Comments
 
Most Helpful

Pharma companies often have a lot of pre-FDA approval drug candidates in their pipelines making their way through the R&D process, and sometimes they are constrained by capital/manpower from investing in all of them simultaneously.

Rather than let some of the perceived less-promising assets languish, they can sell them off to interested parties as lottery tickets that require commitment of time/money (10-100s of $mm) to generate clinical results.

These opportunities will always exist. But you need to be able to spot them. In fact, Roivant (after Vivek left, so without his involvement) bought a TL1A drug Pfizer cast off for $45mm in Dec 2022 and sold to Roche for $7.1bn less than a year later, in Oct 2023

Pretty nice return

https://www.biospace.com/roche-pays-7-1b-to-roivant-for-us-rights-to-te…

 

This was a great answer - thanks for taking the time to respond! I don't know anything about the industry but I find it super fascinating.

Are there specialized firms that tend to buy these lottery tickets?  How could they have a better view of how promising an asset is compared to the pharma company themselves?

If you have any recommendations on learning materials, I'd really appreciate it!

 

Near impossible to learn how to evaluate the prospects of a preclinical drug asset without PhD level basic science training, if that’s what you’re asking…

There’s no shortcuts. You do the science work if you want to be in the business of buying cheap assets to later develop and flip. No there’s no specialist who only does this bc it’s incredibly hard and hit rate is pretty low. There are serial entrepreneurs who go dumpster diving and license something cheap, then launch a company to develop it and hopefully raise funds to do so. Very tough gamr

 

Hmm, let’s see:

  • They were able to buy intepirdine aka RVT-101 for cheap because it was consistently unpromising in phase 2 trials by GSK.
  • After buying the rights, another phase 2 trial was run, concluding: “In this analysis of subjects completing a Phase 2b study in subjects with mild-to-moderate Alzheimer’s disease, the 35 mg dose of RVT-101 was shown to be effective in improving cognition and function”. Bonus fun fact, Vivek’s mother is one of the authors of this study.
  • Axovant IPO'd with no other products, and reaches nearly 3bn peak valuation. Vivek personally has a significant liquidity event shortly after.
  • 2 years pass, and phase 3 trials are nearing completion. The stock pumps ~2x. Softbank Vision fund invests a billion into Roivant, Vivek's holding company that still owns most of Axovant along with a few other 'vants.
  • RVT-101 fails phase 3 trials. The stock tanks and then continues to bleed for a few more years until the company is dissolved.

Yes, a great trade, if you can get it!

 

Fugit eveniet dolor tenetur earum qui itaque consequatur enim. Qui laborum quia neque ad excepturi. Iure eaque perspiciatis aut magnam atque. Tenetur vel officia veniam dolor. Beatae dolorem dolorem vitae omnis. Ex quis maiores odit optio. Fugit alias rerum vitae quia et quo impedit. Sit est ut quidem praesentium.

Cupiditate amet itaque qui nihil possimus non qui. Provident id molestiae omnis at. Nisi molestiae ut quidem aut. Temporibus illo possimus voluptatem ut non molestiae consequatur aut.

Career Advancement Opportunities

June 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.1%
  • Citadel Investment Group 97.1%
  • AQR Capital Management 96.2%
  • Magnetar Capital 95.2%

Overall Employee Satisfaction

June 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • Millennium Partners 98.1%
  • D.E. Shaw 97.1%
  • Blackstone Group 96.1%
  • Citadel Investment Group 95.1%

Professional Growth Opportunities

June 2026 Hedge Fund

  • AQR Capital Management 99.1%
  • Point72 98.1%
  • D.E. Shaw 97.2%
  • Citadel Investment Group 96.2%
  • Magnetar Capital 95.3%

Total Avg Compensation

June 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $423
  • NA (9) $320
  • Engineer/Quant (86) $288
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (76) $192
  • Analysts (240) $181
  • Intern/Summer Associate (28) $146
  • Junior Trader (5) $102
  • Intern/Summer Analyst (282) $96
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
DrApeman's picture
DrApeman
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”